Adam Farag, Andres Kohan, Tetsuro Sekine, Seyed Ali Mirshahvalad, Ur Metser, Sebastian Mafeld, Kongteng Tan, Patrick Veit-Haibach
{"title":"使用18F-FAZA动力学模型测量慢性肢体缺血缺氧-一项初步研究。","authors":"Adam Farag, Andres Kohan, Tetsuro Sekine, Seyed Ali Mirshahvalad, Ur Metser, Sebastian Mafeld, Kongteng Tan, Patrick Veit-Haibach","doi":"10.1186/s13550-025-01243-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic limb- threatening ischemia (CLTI) is a serious condition that can lead to amputation, and in some cases, it can be associated with mortality. Current clinical evaluation methods have several limitations. Therefore, new methods to assess CLTI are needed to better understand and measure underlying causes and functionality, and hence potentially improve the treatment. In this study, we use dynamic <sup>18</sup>F-FAZA PET-imaging as a method of measuring hypoxia as a marker associated with CLTI, on twelve patients identified with CLTI who underwent <sup>18</sup>F-FAZA PET-MR imaging.</p><p><strong>Results: </strong>The kinetic modelling goodness-of-fit metrics using AIF from independent limb with the irreversible-2TC3K model distinguished between index and contralateral limbs better than the reversable-2TC4K model. The Spearman correlation coefficients between the standardized uptake value (SUV) SUV-to-SUV<sub>med</sub> ratio and the perfusion parameter, [Formula: see text], was r<sub>s</sub> = -0.07 for index and r<sub>s</sub> = 0.22 for contralateral limbs. For the SUV-to-SUV<sub>med</sub> ratio correlation with diffusion parameter, [Formula: see text], it is found to be negative for both index (r<sub>s</sub> = -0.16) and contralateral (r<sub>s</sub> = -0.11).</p><p><strong>Conclusions: </strong>The kinetic modelling of <sup>18</sup>F-FAZA dynamic PET-MR was able to differentiate between index and contralateral limbs in CLTI patients, and the diffusion metric from the kinetic modelling can potentially be used as a metric to measure hypoxia in CLTI.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, NCT04054609. Registered 20,190,611, https//clinicaltrials.gov/study/NCT04054609.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"48"},"PeriodicalIF":3.1000,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033150/pdf/","citationCount":"0","resultStr":"{\"title\":\"Measuring hypoxia in chronic limb-threatening ischemia using <sup>18</sup>F-FAZA kinetic modelling - a pilot study.\",\"authors\":\"Adam Farag, Andres Kohan, Tetsuro Sekine, Seyed Ali Mirshahvalad, Ur Metser, Sebastian Mafeld, Kongteng Tan, Patrick Veit-Haibach\",\"doi\":\"10.1186/s13550-025-01243-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Chronic limb- threatening ischemia (CLTI) is a serious condition that can lead to amputation, and in some cases, it can be associated with mortality. Current clinical evaluation methods have several limitations. Therefore, new methods to assess CLTI are needed to better understand and measure underlying causes and functionality, and hence potentially improve the treatment. In this study, we use dynamic <sup>18</sup>F-FAZA PET-imaging as a method of measuring hypoxia as a marker associated with CLTI, on twelve patients identified with CLTI who underwent <sup>18</sup>F-FAZA PET-MR imaging.</p><p><strong>Results: </strong>The kinetic modelling goodness-of-fit metrics using AIF from independent limb with the irreversible-2TC3K model distinguished between index and contralateral limbs better than the reversable-2TC4K model. The Spearman correlation coefficients between the standardized uptake value (SUV) SUV-to-SUV<sub>med</sub> ratio and the perfusion parameter, [Formula: see text], was r<sub>s</sub> = -0.07 for index and r<sub>s</sub> = 0.22 for contralateral limbs. For the SUV-to-SUV<sub>med</sub> ratio correlation with diffusion parameter, [Formula: see text], it is found to be negative for both index (r<sub>s</sub> = -0.16) and contralateral (r<sub>s</sub> = -0.11).</p><p><strong>Conclusions: </strong>The kinetic modelling of <sup>18</sup>F-FAZA dynamic PET-MR was able to differentiate between index and contralateral limbs in CLTI patients, and the diffusion metric from the kinetic modelling can potentially be used as a metric to measure hypoxia in CLTI.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, NCT04054609. Registered 20,190,611, https//clinicaltrials.gov/study/NCT04054609.</p>\",\"PeriodicalId\":11611,\"journal\":{\"name\":\"EJNMMI Research\",\"volume\":\"15 1\",\"pages\":\"48\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-04-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033150/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJNMMI Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13550-025-01243-5\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13550-025-01243-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Measuring hypoxia in chronic limb-threatening ischemia using 18F-FAZA kinetic modelling - a pilot study.
Background: Chronic limb- threatening ischemia (CLTI) is a serious condition that can lead to amputation, and in some cases, it can be associated with mortality. Current clinical evaluation methods have several limitations. Therefore, new methods to assess CLTI are needed to better understand and measure underlying causes and functionality, and hence potentially improve the treatment. In this study, we use dynamic 18F-FAZA PET-imaging as a method of measuring hypoxia as a marker associated with CLTI, on twelve patients identified with CLTI who underwent 18F-FAZA PET-MR imaging.
Results: The kinetic modelling goodness-of-fit metrics using AIF from independent limb with the irreversible-2TC3K model distinguished between index and contralateral limbs better than the reversable-2TC4K model. The Spearman correlation coefficients between the standardized uptake value (SUV) SUV-to-SUVmed ratio and the perfusion parameter, [Formula: see text], was rs = -0.07 for index and rs = 0.22 for contralateral limbs. For the SUV-to-SUVmed ratio correlation with diffusion parameter, [Formula: see text], it is found to be negative for both index (rs = -0.16) and contralateral (rs = -0.11).
Conclusions: The kinetic modelling of 18F-FAZA dynamic PET-MR was able to differentiate between index and contralateral limbs in CLTI patients, and the diffusion metric from the kinetic modelling can potentially be used as a metric to measure hypoxia in CLTI.
EJNMMI ResearchRADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING&nb-
CiteScore
5.90
自引率
3.10%
发文量
72
审稿时长
13 weeks
期刊介绍:
EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies.
The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.